| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Model |
From the Center for Comparative Medicine,* University of California, Davis, California; the Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; the Department of Biochemistry, School of Dentistry, the University of Tokushima, Tokushima, Japan; Boston University, School of Medicine, Boston, Massachusetts; the Department of Human Oncology, University of Wisconsin, Madison, Wisconsin; the Department of Medicine,¶ University of Wisconsin, Madison, Wisconsin; the Department of Medicine,|| Cancer Center, School of Medicine, University of California, San Diego, La Jolla, California; the Division of Life Sciences,** Lawrence Berkeley National Laboratory, University of California, Berkeley, California; and the Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada
To study phenotype-genotype correlations, ErbB/Ras pathway tumors (transgenic for ErbB2, c-Neu, mutants of c-Neu, polyomavirus middle T antigene (PyV-mT), Ras, and bi-transgenic for ErbB2/Neu with ErbB3 and with progesterone receptor) from four different institutions were histopathologically compared with Wnt pathway tumors [transgenes Wnt1, Wnt10b, dominant-negative glycogen synthase kinase 3-ß, ß-Catenin, and spontaneous mutants of adenomatous polyposis coli gene (Apc)]. ErbB/Ras pathway tumors tend to form solid nodules consisting of poorly differentiated cells with abundant cytoplasm. ErbB/Ras pathway tumors also have scanty stroma and lack myoepithelial or squamous differentiation. In contrast, Wnt pathway tumors exhibit myoepithelial, acinar, or glandular differentiation, and, frequently, combinations of these. Squamous metaplasia is frequent and may include transdifferentiation to epidermal and pilar structures. Most Wnt pathway tumors form caricatures of elongated, branched ductules, and have well-developed stroma, inflammatory infiltrates, and pushing margins. Tumors transgenic for interacting genes such as protein kinase CK2
(casein kinase II), and the fibroblast growth factors (Fgf) Int2/Fgf3 or keratinocyte growth factor (Kgf/Fgf7) also have the Wnt pathway phenotype. Because the tumors from the ErbB/Ras and the Wnt pathway are so distinct and can be readily identified using routine hematoxylin and eosin sections, we suggest that pathway pathology is applicable in both basic and clinical cancer research.
Related articles in Am J Pathol:
This article has been cited by other articles:
 |
|
 |
|
  C. E. Glover, K. E. Gurley, K.-H. Kim, B. Storer, M. L. Fero, and C. J. Kemp Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer Carcinogenesis, June 1, 2009; 30(6): 1058 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dourdin, B. Schade, R. Lesurf, M. Hallett, R. J. Munn, R. D. Cardiff, and W. J. Muller Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis Cancer Res., April 1, 2008; 68(7): 2122 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chikama, C.-Y. Liu, J. T.A. Meij, Y. Hayashi, I-J. Wang, L. Yang, T. Nishida, and W. W.Y. Kao Excess FGF-7 in Corneal Epithelium Causes Corneal Intraepithelial Neoplasia in Young Mice and Epithelium Hyperplasia in Adult Mice Am. J. Pathol., March 1, 2008; 172(3): 638 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Trimboli, K. Fukino, A. de Bruin, G. Wei, L. Shen, S. M. Tanner, N. Creasap, T. J. Rosol, M. L. Robinson, C. Eng, et al. Direct Evidence for Epithelial-Mesenchymal Transitions in Breast Cancer Cancer Res., February 1, 2008; 68(3): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Gupta, J. Perk, S. Acharyya, P. de Candia, V. Mittal, K. Todorova-Manova, W. L. Gerald, E. Brogi, R. Benezra, and J. Massague ID genes mediate tumor reinitiation during breast cancer lung metastasis PNAS, December 4, 2007; 104(49): 19506 - 19511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, J.-l. Luo, and M. Karin I{kappa}B kinase {alpha} kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells PNAS, October 2, 2007; 104(40): 15852 - 15857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Akli, C. S. Van Pelt, T. Bui, A. S. Multani, S. Chang, D. Johnson, S. Tucker, and K. Keyomarsi Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway Cancer Res., August 1, 2007; 67(15): 7212 - 7222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kuorelahti, S. Rulli, I. Huhtaniemi, and M. Poutanen Human Chorionic Gonadotropin (hCG) Up-Regulates wnt5b and wnt7b in the Mammary Gland, and hCG{beta} Transgenic Female Mice Present with Mammary Gland Tumors Exhibiting Characteristics of the Wnt/{beta}-Catenin Pathway Activation Endocrinology, August 1, 2007; 148(8): 3694 - 3703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gestl, T. L. Leonard, J. L. Biddle, M. T. Debies, and E. J. Gunther Dormant Wnt-Initiated Mammary Cancer Can Participate in Reconstituting Functional Mammary Glands Mol. Cell. Biol., January 1, 2007; 27(1): 195 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dearth, X. Cui, H.-J. Kim, I. Kuiatse, N. A. Lawrence, X. Zhang, J. Divisova, O. L. Britton, S. Mohsin, D. C. Allred, et al. Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2 Mol. Cell. Biol., December 15, 2006; 26(24): 9302 - 9314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Zinser, M. A. Leonis, K. Toney, P. Pathrose, M. Thobe, S. A. Kader, B. E. Peace, S. R. Beauman, M. H. Collins, and S. E. Waltz Mammary-Specific Ron Receptor Overexpression Induces Highly Metastatic Mammary Tumors Associated with {beta}-Catenin Activation Cancer Res., December 15, 2006; 66(24): 11967 - 11974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Du, K. Podsypanina, S. Huang, A. McGrath, M. J. Toneff, E. Bogoslovskaia, X. Zhang, R. C. Moraes, M. Fluck, D. C. Allred, et al. Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models PNAS, November 14, 2006; 103(46): 17396 - 17401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Namba, L. J.T. Young, C. K. Abbey, L. Kim, P. Damonte, A. D. Borowsky, J. Qi, C. G. Tepper, C. L. MacLeod, R. D. Cardiff, et al. Rapamycin Inhibits Growth of Premalignant and Malignant Mammary Lesions in a Mouse Model of Ductal Carcinoma In situ Clin. Cancer Res., April 15, 2006; 12(8): 2613 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Kwak, S. Kim, J. Zhang, R. D. Cardiff, E. V. Schmidt, and D. A. Haber Mammary Tumorigenesis following Transgenic Expression of a Dominant Negative CHK2 Mutant Cancer Res., February 15, 2006; 66(4): 1923 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cecena, F. Wen, R. D. Cardiff, and R. G. Oshima Differential Sensitivity of Mouse Epithelial Tissues to the Polyomavirus Middle T Oncogene Am. J. Pathol., January 1, 2006; 168(1): 310 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Currier, S. E. Solomon, E. G. Demicco, D. L. F. Chang, M. Farago, H. Ying, I. Dominguez, G. E. Sonenshein, R. D. Cardiff, Z.-X. J. Xiao, et al. Oncogenic Signaling Pathways Activated in DMBA-Induced Mouse Mammary Tumors Toxicol Pathol, October 1, 2005; 33(6): 726 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Bascom, J. E. Fata, Y. Hirai, M. D. Sternlicht, and M. J. Bissell Epimorphin Overexpression in the Mouse Mammary Gland Promotes Alveolar Hyperplasia and Mammary Adenocarcinoma Cancer Res., October 1, 2005; 65(19): 8617 - 8621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhao, Y. Cui, J. Dupont, H. Sun, L. Hennighausen, and S. Yakar Overexpression of the Tumor Suppressor Gene Phosphatase and Tensin Homologue Partially Inhibits Wnt-1-Induced Mammary Tumorigenesis Cancer Res., August 1, 2005; 65(15): 6864 - 6873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sun, L. Strizzi, A. Raafat, M. Hirota, C. Bianco, L. Feigenbaum, N. Kenney, C. Wechselberger, R. Callahan, and D. S. Salomon Overexpression of Human Cripto-1 in Transgenic Mice Delays Mammary Gland Development and Differentiation and Induces Mammary Tumorigenesis Am. J. Pathol., August 1, 2005; 167(2): 585 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Farago, I. Dominguez, E. Landesman-Bollag, X. Xu, A. Rosner, R. D. Cardiff, and D. C. Seldin Kinase-Inactive Glycogen Synthase Kinase 3{beta} Promotes Wnt Signaling and Mammary Tumorigenesis Cancer Res., July 1, 2005; 65(13): 5792 - 5801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Arnes, J.-S. Brunet, I. Stefansson, L. R. Begin, N. Wong, P. O. Chappuis, L. A. Akslen, and W. D. Foulkes Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4003 - 4011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Santos, D. Eggle, and David. J. States Wnt pathway curation using automated natural language processing: combining statistical methods with partial and full parse for knowledge extraction Bioinformatics, April 15, 2005; 21(8): 1653 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Zinser and J. Welsh Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice Carcinogenesis, December 1, 2004; 25(12): 2361 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Lacroix, R-A Toillon, and G Leclercq Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics Endocr. Relat. Cancer, September 1, 2004; 11(3): 497 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gattelli, M. C. Cirio, A. Quaglino, C. Schere-Levy, N. Martinez, M. Binaghi, R. P. Meiss, L. H. Castilla, and E. C. Kordon Progression of Pregnancy-Dependent Mouse Mammary Tumors after Long Dormancy Periods. Involvement of Wnt Pathway Activation Cancer Res., August 1, 2004; 64(15): 5193 - 5199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Namba, J. E. Maglione, L. J.T. Young, A. D. Borowsky, R. D. Cardiff, C. L. MacLeod, and J. P. Gregg Molecular Characterization of the Transition to Malignancy in a Genetically Engineered Mouse-Based Model of Ductal Carcinoma In situ Mol. Cancer Res., August 1, 2004; 2(8): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Y. Liu, S. P. McDermott, S. S. Khwaja, and C. M. Alexander The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells PNAS, March 23, 2004; 101(12): 4158 - 4163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Cardiff, A. Rosner, M. A. Hogarth, J. J. Galvez, A. D. Borowsky, and J. P. Gregg Validation: The New Challenge for Pathology Toxicol Pathol, January 1, 2004; 32(1_suppl): 31 - 39. [Abstract] [PDF]
|
|
|
|
|
|
J. C.L. Schuh Trials, Tribulations, and Trends in Tumor Modeling in Mice Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66. [Abstract] [PDF]
|
|
|
|
|
|
Y. Li, B. Welm, K. Podsypanina, S. Huang, M. Chamorro, X. Zhang, T. Rowlands, M. Egeblad, P. Cowin, Z. Werb, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells PNAS, December 23, 2003; 100(26): 15853 - 15858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Romieu-Mourez, D. W. Kim, S. M. Shin, E. G. Demicco, E. Landesman-Bollag, D. C. Seldin, R. D. Cardiff, and G. E. Sonenshein Mouse Mammary Tumor Virus c-rel Transgenic Mice Develop Mammary Tumors Mol. Cell. Biol., August 15, 2003; 23(16): 5738 - 5754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Andrechek, M. A. Laing, A. A. Girgis-Gabardo, P. M. Siegel, R. D. Cardiff, and W. J. Muller Gene Expression Profiling of Neu-induced Mammary Tumors from Transgenic Mice Reveals Genetic and Morphological Similarities to ErbB2-expressing Human Breast Cancers Cancer Res., August 15, 2003; 63(16): 4920 - 4926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chatterjee, A. Rosner, Y. Han, E. T. Zelazny, B. Li, R. D. Cardiff, and A. S. Perkins Acceleration of Mouse Mammary Tumor Virus-Induced Murine Mammary Tumorigenesis by a p53172H Transgene: Influence of FVB Background on Tumor Latency and Identification of Novel Sites of Proviral Insertion Am. J. Pathol., December 1, 2002; 161(6): 2241 - 2253. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
